May 27, 2023 USPTO approves AliquantumRx Inc.’s patent Salts and Polymorphs of Cethromycin for the Treatment of Bacterial and Protozoan Disease
AliquantumRx Inc., a Johns Hopkins FastForward company supported by Maryland Technology Development Corporation (TEDCO) is proud to announce the approval of its patent “Salts and Polymorphs of Cethromycin for the Treatment of Bacterial and Protozoan Disease”.